Sanofi Completes Acquisition of Dynavax, Expanding Adult Vaccination Presence.

Sanofi has completed the acquisition of Dynavax, a vaccine company, for $15.50 per share. The deal includes Dynavax's hepatitis B vaccine, HEPLISAV-B, and its candidate vaccine for shingles, Z-1018, as well as other vaccine projects in development. The acquisition expands Sanofi's presence in adult vaccinations and combines Dynavax's vaccines with Sanofi's commercial reach, global scale, and development capabilities.